Literature DB >> 17491522

Intratympanic steroids for idiopathic sudden sensorineural hearing loss.

Dennis C Fitzgerald1, John F McGuire.   

Abstract

OBJECTIVES: We undertook to evaluate the effectiveness of intratympanic (IT) steroid injections for treating idiopathic sudden sensorineural hearing loss (ISSHL) by performing a retrospective case series study in a private otology practice.
METHODS: A total of 21 eligible patients with ISSHL were included. We defined ISSHL as a hearing loss of 20 dB or more at at least 3 consecutive audiometric frequencies that develops within 72 hours or less and cannot be attributed to any commonly identifiable cause of sudden hearing loss. Three IT injections of 0.4 mL of 62.5 mg/mL methylprednisolone solution were administered 1 week apart. The end point for the study was a clinically significant change in audiometric values, with a positive response determined to be a 10-dB or greater improvement in the 4-tone pure tone average and/ or a 15% or greater improvement in the word discrimination score. Audiometric data were recorded just before therapy and 1 week after the last IT treatment. The potentially confounding variables recorded included age, sex, "prompt treatment" (defined as treatment within 14 days from onset), concurrent or prior treatment with oral steroids, and severity of hearing loss.
RESULTS: The overall response rate to the IT steroid protocol was 67% (14 of 21 patients), with a 95% confidence interval of 43% to 85%. Backward stepwise logistic regression identified "prompt treatment" as the only variable that significantly affected the outcome. The response rate of the "prompt treatment" cohort was 91% (10 of 11 patients), with a 95% confidence interval of 59% to 100%.
CONCLUSIONS: These findings support the use of IT steroids as an early intervention in the treatment of ISSHL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17491522     DOI: 10.1177/000348940711600405

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  7 in total

Review 1.  Issues, indications, and controversies regarding intratympanic steroid perfusion.

Authors:  Mohamed Hamid; Dennis Trune
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 2.064

2.  The efficiency of intratympanic dexamethasone injection as a sequential treatment after initial systemic steroid therapy for sudden sensorineural hearing loss.

Authors:  Jong Bin Lee; Seong Jun Choi; Keehyun Park; Hun Yi Park; Oak-Sung Choo; Yun-Hoon Choung
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-08       Impact factor: 2.503

Review 3.  Are intra-tympanically administered steroids effective in patients with sudden deafness? Implications for current clinical practice.

Authors:  Petros V Vlastarakos; George Papacharalampous; Paul Maragoudakis; George Kampessis; Nicholas Maroudias; Dimitrios Candiloros; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-08-19       Impact factor: 2.503

4.  Efficacy comparison of oral steroid, intratympanic steroid, hyperbaric oxygen and oral steroid + hyperbaric oxygen treatments in idiopathic sudden sensorineural hearing loss cases.

Authors:  Yalcin Alimoglu; Ender Inci; Deniz Tuna Edizer; Alper Ozdilek; Mehmet Aslan
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-23       Impact factor: 2.503

5.  Management of acute idiopathic sensorineural hearing loss: a survey of UK ENT consultants.

Authors:  S J Jarvis; V Giangrande; G John; A R D Thornton
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-04       Impact factor: 2.124

6.  Early posttreatment audiometry underestimates hearing recovery after intratympanic steroid treatment of sudden sensorineural hearing loss.

Authors:  Benjamin J Wycherly; Jared J Thompkins; H Jeffrey Kim
Journal:  Int J Otolaryngol       Date:  2011-11-28

7.  Treatment of Long-term Sudden Sensorineural Hearing Loss as an Otologic Migraine Phenomenon.

Authors:  Khodayar Goshtasbi; Janice T Chua; Adwight Risbud; Brooke Sarna; Shahrnaz Jamshidi; Mehdi Abouzari; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2021-08-01       Impact factor: 2.619

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.